FEATURED NEWS FROM CCII
-
Press ReleasesDesign for Science
CCII's New home, the Bristol Myers Squibb Building at the Center for Cancer Immunotherapy and Immunobiology at the Kyoto University campus, has been made possible by funding from the Japanese government and a generous donation from pharmaceutical giant Bristol Myers Squibb. In addition, Tadao Ando, one of Japan’s foremost contemporary architects, provided invaluable support by supervising the grand design of the building’s exterior and interior.
-
ResearchPD-1 & the Immune Therapy Revolution: A 30-Year Journey
With the advent of PD-1 checkpoint inhibitors, specially designed antibodies that prevent the PD-1 protein from blocking immune cells to fight cancer, the idea of enrolling the immune system in the fight against cancer has finally become a clinical reality. However, there are still cancer patients that do not respond to PD-1 antibodies, and further research is needed to improve existing approaches.
-
ResearchRethinking the Immune Response as Metabolic Process
Immune responses are energetically expensive. Not surprisingly, secreted metabolites are increasingly emerging as important factors in immune cell maturation and activation, as this new review published in Trends in Immunology by Sidonia Fagarasan et al. demonstrates.
-
ResearchSpermidine to the Rescue?
Spermidine, a polyamine compound found in ribosomes and living tissues and originally isolated from semen, is an increasingly popular anti-aging supplement. Muna Al-Habsi and her colleagues demonstrate in a new paper published in Science that spermidine can enhance cancer immunotherapy blocking the PD-1 pathway by reversing aging effects in killer T-cells.
-
ResearchImmunology as the Ultimate System Biology
In a new paper published in Nature by Prof. Sidonia Fagarasan and colleagues demonstrate that the neurotransmitter GABA plays a surprising role in orchestrating complex interactions between various immune cells. While GABA is shown to reduce autoimmune inflammation, it can equally impair the immune reaction against cancer.
-
RecruitWe are permanently recruiting!
We are permanently recruiting highly motivated students, postdoctoral fellows, scientists, and technical staff. Please contact us!